Welcome to our dedicated page for Myriad Genetics SEC filings (Ticker: MYGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Myriad Genetics Inc. filings document the regulatory record of a molecular diagnostics and precision medicine company. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary revenue and test-volume information, guidance, and product-related operating updates tied to Cancer Care Continuum, Prenatal Health, Mental Health, Precise MRD, and MyChoice CDx.
The company's proxy materials cover board matters, executive compensation, equity awards, and annual meeting governance. Other current reports document officer transitions, compensatory arrangements, and amendments to previously furnished earnings materials, providing formal disclosure of governance changes and financial-reporting corrections.
Barclays PLC reported beneficial ownership of 4,899,951 shares of Myriad Genetics common stock, equal to 5.31% of the class. The filing shows Barclays has sole voting and dispositive power over 4,762,680 shares and shared voting and dispositive power over 137,271 shares. The reporting person is classified as HC and the filing identifies related subsidiaries as Barclays Bank PLC, Barclays Capital Inc, Barclays Capital Securities Ltd.
This document is a Schedule 13G disclosure and includes a certification that the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence the control of the issuer.